Previous Close | 316.43 |
Open | 317.23 |
Bid | 317.28 x 800 |
Ask | 317.32 x 1400 |
Day's Range | 315.20 - 318.00 |
52 Week Range | 208.34 - 321.60 |
Volume | 338,840 |
Avg. Volume | 1,355,242 |
Market Cap | 127.012B |
Beta (3Y Monthly) | 1.12 |
PE Ratio (TTM) | 35.63 |
EPS (TTM) | 8.89 |
Earnings Date | Jan 28, 2020 - Feb 3, 2020 |
Forward Dividend & Yield | 0.76 (0.24%) |
Ex-Dividend Date | 2019-12-16 |
1y Target Est | 321.13 |
Thermo Fisher (TMO) gains from solid overseas expansion and acquisitions.
Patterson Companies' (PDCO) Q2 results benefit from higher revenues, gross margin expansion and solid show by Dental segment.
Better-than-expected performance at both Medical and Dental segments is likely to have driven Cantel Medical (CMD) in Q1 earnings.
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
A series of product launches with better precision medicine initiatives aids Thermo Fisher's (TMO) performance.
The Zacks Analyst Blog Highlights: Procter & Gamble, Thermo Fisher, PayPal, NextEra Energy and Enterprise Products
Better-than-expected performance at CVI and CSI, and higher revenues are likely to have aided Cooper Companies (COO) in Q4 earnings.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 52% and 49% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
Top Analyst Reports for Procter & Gamble, Thermo Fisher & PayPal
Veeva (VEEV) gains from solid segmental contributions in fiscal third quarter, raises fiscal 2020 view.
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the appointment of Maggie Yuen as CFO of Penumbra, effective December 2, 2019.
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar performance.
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
Investors with a long-term horizong may find it valuable to assess Thermo Fisher Scientific Inc.'s (NYSE:TMO) earnings...
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 750 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of September […]
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Robust product portfolio and higher revenues are likely to have benefited Veeva Systems (VEEV) in third-quarter fiscal 2020 earnings.
Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.
NEW YORK , Nov. 19, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO) will replace Celgene Corp. (NASD: CELG) in the S&P 100, and ServiceNow Inc. (NYSE: NOW) will replace Celgene in the S&P ...
Medtronic (MDT) demonstrates improved performances at CER, banking on growth in all major business segments and geographies.
ServiceNow Inc. will replace Celgene Corp. in the S&P 500 index before the open on Thursday, S&P Global said late Monday. Bristol-Myers Squibb Co. is acquiring Celgene in a deal expected to close soon. Lab equipment maker Thermo Fisher Scientific Inc. will join the S&P 100, S&P Global said in the statement. ServiceNow, a cloud computing company based in Santa Clara, Calif., said earlier Monday that Gina Mastantuono will be its new chief financial officer effective Jan. 13. Shares were 4% higher in the extended session, after ending the regular trading day up 2.4%.
Canopy Growth (CGC) reports mixed fiscal second-quarter results on strength in its core segments.
Shares of Dutch genetic testing company Qiagen shot higher on Monday, after the company confirmed it had entered into discussions to “explore potential strategic alternatives” after receiving ”several nonbinding indications of interest.”
Dutch genetic-testing company Qiagen confirmed late Friday it's fielding several offers from potential suitors interested in acquiring it. Qiagen stock rose 8.8% on Friday.